1-5 of 5
Nissim Haim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients

Farge Dominique, Debourdeau Philippe, Beckers Marielle, Caroline Baglin, Rupert Bauersachs, Benjamin Brenner, MD, Dialina Brilhante, MD, Anna Falanga, MD, Grigoris T Gerotziafas, Nissim Haim, Ajay Kakkar, MD, Alok A. Khorana, MD, Ramon Lecumberri, Mario Mandala, Michel Marthy, Manuel Monreal, MD, PhD, Shaker S Mousa, Simon Noble, Ingrid Pabinger, MD, Paolo Prandoni, Martin Prins, MD, PhD, Mohammed H. Qari, Michael B. Streiff, MD, Konstantin Syrigos, Henri Bounameaux, MD, Harry Roger Buller, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1161.
https://doi.org/10.1182/blood.V120.21.1161.1161
Published: 2012
Journal Articles

International Clinical Practice Guidelines for the Treatment and Prophylaxis of Thrombosis Associated with Central Venous Catheters in Patients with Cancer

Debourdeau Philippe, Farge Dominique, Beckers Marielle, Caroline Baglin, Rupert Bauersachs, Benjamin Brenner, MD, Dialina Brilhante, MD, Anna Falanga, MD, Grigoris T Gerotziafas, Nissim Haim, Ajay Kakkar, MD, Alok A. Khorana, MD, Ramon Lecumberri, Mario Mandala, Michel Marty, Manuel Monreal, MD, PhD, Shaker S Mousa, Simon Noble, Ingrid Pabinger, MD, Paolo Prandoni, Martin Prins, MD, PhD, Mohammed H. Qari, Michael B. Streiff, MD, Konstantin Syrigos, Harry Roger Buller, MD, PhD, Henri Bounameaux, MD
Journal: Blood
Blood (2012) 120 (21): 4357.
https://doi.org/10.1182/blood.V120.21.4357.4357
Published: 2012
Journal Articles

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Eldad J. Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Nissim Haim, MD, Irit Avivi, MD, Diana Gaitini, MD, Menachem Ben-Shachar, MD, Ora Israel, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD
Journal: Blood
Blood (2006) 108 (11): 4589.
https://doi.org/10.1182/blood.V108.11.4589.4589
Published: 2006
Journal Articles

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Clinical Trials & Observations
Eldad J. Dann, Rachel Bar-Shalom, Ada Tamir, Nissim Haim, Menachem Ben-Shachar, Irit Avivi, Tzila Zuckerman, Mark Kirschbaum, Odelia Goor, Diana Libster, Jacob M. Rowe, Ron Epelbaum
Journal: Blood
Blood (2006) 109 (3): 905–909.
https://doi.org/10.1182/blood-2006-04-019901
Published: 2006
Journal Articles

Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.

Eldad J. Dann, MD, Rachel Bar Shalom, MD, Nissim Haim, MD, Ada Tamir, Ph.D, Menachem Ben Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Mark Kirschbaum, MD, Odelia Goor, MD, Diana Libster, MD, Jacob M. Rowe, MD, Ron Apelbaum, MD
Journal: Blood
Blood (2005) 106 (11): 815.
https://doi.org/10.1182/blood.V106.11.815.815
Published: 2005